For a company deeply tied to the highs and setbacks of Alzheimer’s drug research, yesterday’s market reaction to new trial data from Biogen Inc (NASDAQ:BIIB, XETRA:IDP) looked brutally familiar.
After an initial jump following the update, shares in the US biotech giant fell more than 6% overnight after the group reported mixed Phase 2 results for diranersen (formerly BIIB080), its experimental tau-targeting Alzheimer’s therapy. The study technically failed its primary endpoint — normally a major red flag in biotech — yet Biogen is still pushing ahead towards registrational development.
The pairing of statistical disappointment with management optimism has left investors trying to work out whether this was another warning sign for Alzheimer’s drug development or the early outline of something potentially more important.
Biogen’s CELIA study tested diranersen in patients with early Alzheimer’s disease. Unlike currently approved anti-amyloid therapies, the drug targets tau, another protein widely believed to play a central role in neurodegeneration and cognitive decline.
Tau has long been viewed as one of the field’s most important but elusive targets.
Tau moves closer to centre stage
Biogen said the study did not achieve its primary goal of demonstrating a clear dose-response relationship on the Clinical Dementia Rating-Sum of Boxes scale after 76 weeks.
Ordinarily, that would be expected to severely damage a drug program.
But the company simultaneously argued the trial delivered something the industry has never seen before: evidence that directly lowering tau pathology may also translate into cognitive benefit in Alzheimer’s patients.
The problem — and the reason investors reacted so cautiously — was that the data appeared inconsistent.
Biogen reported that all dose groups showed slowing of cognitive decline, but the strongest effect emerged in the lowest-dose cohort rather than the highest. Analysts immediately questioned whether the efficacy signal was robust enough to justify expensive late-stage development.
The company also withheld much of the detailed efficacy data ahead of a future medical presentation, adding further uncertainty.
Still, beneath the share price reaction, the results may be more strategically important than they initially appear.
For years, Alzheimer’s drug development has been dominated by the amyloid hypothesis — the idea that removing amyloid plaque buildup from the brain can slow disease progression. That approach finally produced approved drugs including Leqembi after decades of failures, but questions remain around efficacy, safety, patient selection and commercial uptake.
Tau has increasingly emerged as the next frontier.
Many researchers now believe amyloid may trigger disease progression while tau accumulation more directly drives neurodegeneration and cognitive decline. If that theory proves correct, future Alzheimer’s treatment may ultimately involve combination approaches targeting both pathways simultaneously.
That possibility helps explain why Biogen appears determined to continue despite the headline miss.
Investors still carry Alzheimer’s scars
The market’s scepticism also reflects Biogen’s complicated history in Alzheimer’s.
The company became one of biotech’s most controversial names following the turbulent approval and eventual commercial collapse of Aduhelm, the anti-amyloid therapy that triggered enormous debate over efficacy standards, pricing and regulatory oversight.
Investors now appear far less willing to reward early Alzheimer’s optimism without exceptionally clear data.
That caution is understandable. Alzheimer’s trials remain among the most expensive, lengthy and failure-prone programs anywhere in biotechnology. Even modest ambiguity can wipe billions from valuations.
Yesterday’s sell-off suggested many investors saw the CELIA update as falling short of the kind of breakthrough moment needed to fully restore confidence in the tau field.
Yet there was another layer to Biogen’s trading story overnight.
Apellis deal adds another growth driver
Alongside the Alzheimer’s update, Biogen also completed its acquisition of Apellis Pharmaceuticals, bringing commercial drugs EMPAVELI and SYFOVRE into its portfolio.
The roughly US$5.3 billion–5.6 billion deal significantly expands Biogen’s exposure to immunology, nephrology and ophthalmology while adding near-term revenue growth drivers outside its traditional neuroscience base.
Biogen said the acquired products generated US$689 million in revenue during 2025 and are expected to support earnings growth through the end of the decade.
That broader diversification strategy may partly explain why the company appears increasingly willing to continue taking calculated risks in Alzheimer’s research.
The market may have punished the CELIA results in the short term, but the bigger picture for biotech investors is harder to ignore: after decades of repeated setbacks, the Alzheimer’s pipeline is finally starting to expand beyond amyloid alone.
Whether tau therapies ultimately succeed remains uncertain. But for the first time in years, the field may finally be broadening into something that looks more like a multi-target treatment landscape rather than a one-theory bet.